title: Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis.
abstract: We performed a randomized controlled study to determine the efficacy of add-backed therapy by every-other-day administration of 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) on GnRH agonists (GnRH-a) treatment in Japanese women with symptomatic endometriosis. At the end of treatment, serum estrone and estradiol levels in the add-back group (n = 11) were significantly higher than those in the control group (n = 10). The assessment of Beecham classification by bimanual examination, serum CA-125 levels, and the frequency of genital bleeding revealed no significant differences between the two groups. The add-back group showed reduced Kupperman indices relative to those of the control group, and could prevent the loss of bone density. These findings led to a conclusion that GnRH-a therapy added back by every-other-day administration of 0.625 mg CEE and 2.5 mg MPA was a safe and effective treatment for Japanese women with endometriosis.
authors.affiliation: Department of Obstetrics and Gynecology, University of Tokushima, School of Medicine, Tokushima, Japan. irahara@clin.med.tokushima-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Irahara
authors.forename: H
authors.initials: H
authors.lastname: Uemura
authors.forename: T
authors.initials: T
authors.lastname: Yasui
authors.forename: H
authors.initials: H
authors.lastname: Kinoshita
authors.forename: M
authors.initials: M
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Tezuka
authors.forename: M
authors.initials: M
authors.lastname: Kiyokawa
authors.forename: M
authors.initials: M
authors.lastname: Kamada
authors.forename: T
authors.initials: T
authors.lastname: Aono
mesh_terms: D000328:Adult; D000818:Animals; D015519:Bone Density; D016723:Bone Remodeling; D018394:CA-125 Antigen / Q000097:blood; D004715:Endometriosis / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D004970:Estrone / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006736:Horses; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008875:Middle Aged; D014592:Uterine Hemorrhage / Q000453:epidemiology
chemical_list: D018394:CA-125 Antigen; D004966:Estrogens, Conjugated (USP); D004970:Estrone; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide